Genome-wide investigation of differentially expressed alternative splicing and RNA-binding protein genes association with AML drug resistance

doi:10.21203/rs.3.rs-4690005/v1

Download PDF

Research Article

Genome-wide investigation of differentially expressed alternative splicing and RNA-binding protein genes association with AML drug resistance

https://doi.org/10.21203/rs.3.rs-4690005/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Background Acute myeloid leukaemia (AML) is a malignancy of the haematopoietic system with extremely high mortality. Current AML therapies, such as chemotherapy, hematopoietic stem cell transplantation, and targeted therapy, have greatly improved the prognosis of AML patients. However, there are still a number of AML patients who develop drug resistance after pharmacotherapy, leading to poor prognosis and relapse. Currently, the global 5-year survival rate for adults with AML remains below 50%. Therefore, it is urgent to identify the aetiology for AML relapse and drug resistance.

Methods Bone marrow mononuclear cells were isolated from bone marrow blood samples from 4 patients with AML relapse, 3 patients with AML remission and 5 control donors by density gradient centrifugation using Lymphocyte separation medium. After RNA extraction and sequencing, differentially expressed genes (DEGs) analysis, overlapping analysis, WGCNA and co-expression analysis, alternative splicing analysis and functional enrichment analysis were further performed.

Results RNA sequencing andDEGs analysis demonstrated that a total of 593 overlapped up-regulated genes and 999 overlapped down-regulated genes were discovered in the reAML group in comparison to the Healthy and AML groups. Of particular, further overlapping analysis revealed that 33 RBP genes were overlapped up-regulated and 30 RBP genes were overlapped down-regulated in the reAML group. Further WGCNA and alternative splicing analyses highlighted that significant changes were found in AS in the reAML group compared with the AML and Healthy groups, and multiple differential regulatory alternative splicing genes (RASGs) and regulatory alternative splicing events (RASEs) were also identified.

Conclusions The aberrance of regulatory alternative splicing (RAS) and differential expression of RNA-binding protein (RBP) genes are highly associated with AML relapse and drug resistance in AML patients.

Acute myeloid leukaemia (AML)

differentially expressed genes (DEGs)

RNA-binding proteins (RBPs)

alternative splicing (AS)

drug resistance

Acute myeloid leukaemia (AML) is a malignant disorder characterised by abnormal growth and differentiation of haematopoietic stem cells (HSCs), in which immature myeloid precursors (myeloblasts) accumulate in the bone marrow and peripheral blood, interfering with normal haematopoietic function [1]. Over the past decades, much effort has been devoted to improving the understanding of AML pathophysiology, and many promising new therapies targeting diverse cellular mechanisms have either been approved or are progressing through clinical trials [2–4]. However, in the last decades, the incidence of AML has gradually increased globally, and the five-year survival rate of patients with AML remains poor, highlighting the urgent need for novel and synergistic therapies [5, 6].

The pathophysiological process involved in AML is extremely intricate, and includes an anomaly in the cell proliferation, differentiation, and apoptosis pathways. Currently, the pathogenesis of AML has been deeply investigated, and the corresponding standard therapy combined with a targeted strategy has already been widely adopted. For instance, the FLT-3 inhibitor midostaurin is commonly used in combination therapy for AML patients with FLT-3 mutations [7]. However, the leading cause of AML-related deaths remains treatment failure due to refractory or recurrent AML, which is caused by drug resistance [8]. Studies have shown that the emergence of numerous drug resistance mechanisms is highly related to the alteration of drug transport and metabolism, such as impaired drug uptake, enhanced drug degradation or efflux, loss of prodrug metabolism activation, and changes in target enzymes [9]. Therefore, renewing appropriate pharmaceuticals targeting AML drug resistance-associated genes is a current focus in various treatment strategies, including frontline, relapsed/refractory and minimal residual disease [8], which would play a crucial role in improving the survival rate and in prolonging overall survival of AML patients.

The regulation mechanism of alternative splicing (AS) has a profound influence on gene expression in higher eukaryotes. Most mammalian pre-mRNAs are alternately spliced in a manner that alters the open reading frame, which not only enables the regulation of gene expression levels but also ensures a high degree of gene-product diversity [10]. In humans, AS occurs in almost all genes containing multiple introns, wherein RNA polymerase II plays a vital role in pre-mRNA splicing [11]. It is noteworthy that approximately 15% of human genetic diseases and cancers are strongly associated with abnormal alternative splicing [12]. In particular, recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events have been recognised as prominent components of AML. Research revealed that aberrant splicing can lead to expression alterations of tumour suppressors and oncogenes and to dysregulation of the apoptosis signalling network, thus influencing the drug resistance of AML cells [13]. Therefore, a better understanding of AS characteristics in AML drug resistance and progression is necessary to design appropriate therapeutic strategies recognising specific alternatively spliced or mutated oncogenic targets.

RNA-binding proteins (RBPs) are proteins that can regulate gene expression and function by binding to RNA with highly dynamic spatio-temporal regulatory features [14]. In the cellular dynamics of RNA transcription and post-transcriptional AS, RNA modification, transport, translation, and degradation, there are a variety of specific RBPs that bind to RNA to exhibit its substantial regulatory function. Abnormal expressions or depletions of RBPs play a key role in the drug resistance and progression of AML, and are, therefore, potential therapeutic targets [15]. For example, Sun et al. demonstrated that circMYBL2, a non-coding RNA from mybl2, can promote the binding of RBP PTBP1 to FLT3-ITD mRNA, therefore upregulating the expression level of FLT3-ITD proteins and further enhancing the resistance of AML cells to quizartinib both in vitro and in vivo [16]. Interestingly, it was also reported that depletion in AML cells of PIWIL4, a germ stem cell-associated RBP belonging to the RNase H-like superfamily, can lead to uncontrolled R-loop formation, transcriptional stagnation, DNA damage, greater sensitivity to pharmacological inhibition of the anti-thrombin receptor (ATR) pathway, and further pharmacologically actionable dependency in AML cells [17, 18]. However, the overall regulatory mechanism by which RBPs form drug resistance in AML remains unclear.

In this study, we hypothesised that the differential expression of RBPs is involved in post-transcriptional regulation in relapsed AML patients undergoing medication, thereby causing the occurrence of AS in mRNA precursors, and speculated that the regulatory axis of RBP-AS may play a vital molecular regulatory role in the formation of drug resistance in AML. Herein, we selected bone marrow blood from patients with AML relapse (reAML), patients with AML remission (AML), and Healthy donors as research objects. Subsequently, by using modern RNA sequencing (RNA-seq) and bioinformatics analysis methodologies, the differentially expressed RBPs and AS genes were obtained, and further mechanistic analyses were performed by applying gene ontology (GO), the Kyoto Encyclopedia of Genes and Genomes (KEGG), protein-protein interaction (PPI), and weighted gene co-expression network analysis (WGCNA). Ultimately, we aimed to explore the probable underlying mechanisms of aberrant RBPs and AS regulators in guiding the formation of drug resistance in AML and expected to lay a solid foundation for further exploration of novel drugs targeting AML resistance.

Patient samples

Bone marrow blood samples from 4 patients with AML relapse, 3 patients with AML remission and 5 control donors were obtained at the Affiliated Hospital of Shandong University of Traditional Chinese Medicine, China. Control samples were obtained from healthy donors of hematopoietic stem cells. Informed consent was obtained in accordance with the Declaration of Helsinki. Bone marrow blood samples were acquired with the informed consent of the donors. The use of human tissues was approved by the Medical Institutional Ethics Committee of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine, China. Approval no., (2023) Review No.(143)-KY. Bone marrow mononuclear cells were isolated by density gradient centrifugation using Lymphocyte separation medium (Solarbio, China).

RNA extraction and sequencing

Total RNA was treated with RQ1 DNase (Promega, USA) to remove DNA. The quality and quantity of the purified RNA were determined by measuring the absorbance at 260 nm/280 nm (A260/A280) using SmartSpec Plus (BioRad, USA). RNA integrity was further verified by 1.5% agarose gel electrophoresis.

For each sample, 1 µg of total RNA was used for RNA-seq library preparation. mRNAs were captured by VAHTS mRNA Capture Beads (Vazyme, N401, USA). The purified RNA was treated with RQ1 DNase (Promega, USA) to remove DNA before being used for directional RNA-seq library preparation by VAHTS Universal V8 RNA-seq Library Prep Kit for Illumina (Vazyme, NR605, USA). Polyadenylated mRNAs were purified and fragmented. Fragmented mRNAs were converted into double strand cDNA. Following end repair and A tailing, the cDNA was ligated to Adaptor (Vazyme, N323, USA). After purification of the ligation product and size fractioning to 300–500 bps, the ligated products were amplified, purified, quantified, and stored at -80℃ before sequencing. The strand marked with dUTP (the 2nd cDNA strand) was not amplified, allowing strand-specific sequencing.

For high-throughput sequencing, the libraries were prepared following the manufacturer's instructions and applied to the Illumina Novaseq 6000 system for 150 nt paired-end sequencing.

RNA-seq raw data cleaning and alignment

Raw reads containing more than 2-N bases were first discarded. Then adaptors and low-quality bases were trimmed from raw sequencing reads using a FASTX-Toolkit (Version 0.0.13). The short reads less than 16 nt were also dropped. After that, clean reads were aligned to the GRCh38 genome by HISAT2 with an allowance of 4 mismatches [19]. Uniquely mapped reads were used for gene reads number counting and fragments per kilobase of transcript per million fragments mapped (FPKM ) calculation [20].

Differentially expressed genes (DEGs) analysis

The R Bioconductor package DESeq2 was utilized to screen out differentially expressed genes [21]. The P value for correction < 0.05 and fold change > 2 or < 0.5 were set as the cut-off criteria for identifying DEGs.

Immune-related genes

1,793 immune-related genes (https://www.immport.org/shared/genelists) were retrieved from the ImmPort database.

WGCNA and co-expression analysis

To fully understand the gene expression pattern, we applied WGCNA to cluster genes that have similar expression patterns within the default parameters [22]. All expressed genes were used as input data. Eigengenes for each clustering module were used as the genes’ representative expression pattern in each module. To explore the regulatory mode between lncRNAs and their host mRNAs, we calculated the Pearson’s correlation coefficients (PCCs) between them and classified their relation into three categories: positively correlated, negatively correlated, and non-correlated.

Alternative splicing analysis

The alternative splicing events (ASEs) and regulatory alternative splicing events (RASEs) between the samples were defined and quantified using the ABLas pipeline as described previously [23, 24]. ABLas detection showed that the types of ASEs were based on the splice junction reads, including exon skipping (ES), alternative 5' splice site (A5SS), alternative 3' splice site (A3SS), mutually exclusive exons (MXE), mutually exclusive 5' UTRs (5pMXE), mutually exclusive 3' UTRs (3pMXE), cassette exons, A3SS&ES, and A5SS&ES.

Functional enrichment analysis

To sort out functional categories of DEGs, GO terms and KEGG pathways were identified using the KOBAS 2.0 server [25]. A hyper geometric test and Benjamini-Hochberg FDR controlling procedures were used to define the enrichment of each term.

Statistical analysis

Statistical differences between two groups (i.e., reAML vs. Healthy & reAML vs. AML) were analysed using a student’s t-test with SPSS Statistics software v.28.0. Data were expressed as means ± standard error of mean (SEM). *p < 0.05 was considered as statistically significant.

RNA-seq analysis of differential gene expression in AML drug-resistant patients

To assess the profile of DEGs in AML relapse (reAML) patients, we performed RNA-seq analysis of bone marrow blood samples from reAML patients, AML remission patients (AML), and Healthy individuals. The results showed that the gene expression profile of reAML patients was significantly altered. Specifically, reAML patients had a total of 2,222 up-regulated genes and 2,413 down-regulated genes compared with Healthy controls. A total of 656 genes were up-regulated, and 1,115 genes were down-regulated compared with AML samples (Fig. 1A, B). Subsequent overlapping analysis revealed a total of 593 overlapped up-regulated genes and 999 overlapped down-regulated genes in the reAML group in comparison to the Healthy and AML groups (Fig. 1C).

Further analyses showed that the overlapped up-regulated GO biological processes were mainly enriched in signal transduction, angiogenesis, cell differentiation, and negative regulation of osteoblast differentiation, while the overlapped down-regulated processes were mainly enriched in immunoglobulin production, immune response, the cell surface or B cell receptor signalling pathway, inflammatory response, and T cell activation (Fig. 1D, E). In addition, the overlapped up-regulated KEGG pathways were largely cancer-associated pathways, such as the Rap1 signalling pathway, transcriptional misregulation in cancer, and the PI3K-Akt and MAPK signalling pathways, while the overlapped down-regulated pathways were largely immune-related and inflammatory pathways, such as hematopoietic cell lineage, primary immunodeficiency, the T cell receptor signalling pathway, graft-versus-host disease, Th17 cell differentiation, and natural killer (NK) cell-mediated cytotoxicity (Additional file 1: Fig. S1A, B). The GO and KEGG results both indicated that the overlapped down-regulated genes were mainly focused on the regulation of immunity and inflammation. Subsequently, we used the known immune genes in the “Immport” immune gene bank as a control and further screened 237 total overlapped down-regulated immune-related genes (Fig. 1F).

Of particular interest, four overlapped up-regulated genes (EGFL7, CBX2, SOX4, and CDK6) and four overlapped down-regulated genes (LCN2, CYBB, RNAS, and CD48) were found to be significantly altered in their expression levels in the reAML group (p < 0.001) (Additional file 1: Fig. S1C). Similarly, the clinical data on acute myeloid leukaemia (LAML) from the TCGA database showed that the expression levels of IGF2BP2, CDK6, and SOX4 were significantly up-regulated in patients with AML relapse (p < 0.05) (Additional file 1: Fig. S2). This suggested that the expression profile of these DEGs is considerably changed in the disease state of AML relapse, which may be one of the prime reasons for progression and drug resistance in AML relapse patients.

RNA-seq analysis of differential RBP expression in AML drug-resistant patients.

In order to clarify the differential expression of RBP genes in reAML patients, we conducted overlapping analysis of overlapped up-regulated and down-regulated genes, as well as RBP genes. The results demonstrated that 33 RBP genes were overlapped up-regulated and 30 RBP genes were overlapped down-regulated (Fig. 2A). In-depth protein-protein interaction (PPI) analysis confirmed a close relationship between the overlapped RBP genes (Fig. 2B). In particular, the expression levels of two overlapped up-regulated (NPM1 & IGF2BP2) and two overlapped downregulated (MYH9 & LGALS3) RBP genes were significantly varied (Fig. 2C). The results indicated that these differentially expressed RBPs are closely related to the development of AML and are very likely involved in the regulation of AML relapse, which may also be one of the key regulatory mechanisms of the progression of AML relapse and drug resistance.

WGCNA of differential AS in AML drug-resistant patients.

To explore the variations of AS in reAML patients, we then carried out in-depth analyses of bone marrow blood samples from the reAML, AML, and Healthy groups. The results demonstrated significant changes in AS in the reAML group in comparison to the AML and Healthy groups, and multiple differential regulatory alternative splicing events (RASEs) were also identified (Fig. 3A, B). We further conducted WGCNA of all the detected regulatory alternative splicing genes (RASGs) and found that these genes were divided into 9 modules (Fig. 3C). According to the different gene expressions in the modules, the turquoise and yellow modules were selected for specific gene expression analyses. The results showed that the expression level of RASG in the turquoise module was increased in the AML and Healthy groups, and decreased in the reAML group. However, in the yellow module, the expression level of RASG was down regulated in the AML and Healthy groups, and up regulated in the reAML group (Fig. 3C). The above results implied that both RASGs and RASEs are altered in reAML patients, showing that they are likely another important factor in the progression of AML relapse and resistance.

Clinical data analysis of differential RAS gene expression in AML drug-resistant patients.

In order to identify the biological processes that closely related to AML in the turquoise and yellow modules, we performed GO analysis on RASGs for both modules. The results clarified that the GO biological processes in the turquoise module were largely enriched in RNA splicing, mRNA processing, splicesomal complex assembly, positive regulation of DNA template transcription, DNA repair, phagocytosis, and protein stabilisation. However, the GO biological processes in the yellow module were mainly enriched in positive regulation of DNA-templated transcription and both the positive and negative regulation of transcription by RNA polymerase II (Fig. 4A). To further identify the specific RASGs that were differentially expressed, we conducted an in-depth analysis of the relative expression levels of RASGs in both the turquoise and yellow modules. The results confirmed that three genes (GRK6, FLNA, and NCOR2) in the turquoise module and three genes (INF2, MGAT1, and NT5C2) in the yellow module in the reAML group were significantly down regulated compared with the AML and Healthy groups (Fig. 4B). Therefore, it is speculated that the differentially expressed RASGs may play a vital role in the regulation of key RASEs in the progression of AML relapse and drug resistance by altering numerous intricate biological processes, such as RNA splicing, transcriptional regulation, and protein stabilisation.

After pharmacotherapy, patients with AML may develop genetic and epigenetic changes that further lead to the enhancement of drug resistance, increasing the difficulties of subsequent therapies [26, 27]. For example, cytarabine (Ara-C) acts in vivo through activation by deoxycytidine kinase phosphorylation to cytarabine triphosphate. However, a majority of relapsed or drug-resistant AML patients have mutations in the deoxycytidine kinase gene, resulting in increased resistance to pharmacotherapy and eventual treatment failure [28]. Recently, studies have shown that mRNA methylation under the regulation of methyltransferase 3 (METTL3) may be involved in the regulation of drug resistance in AML [29, 30]. Here, we report the significant alteration in global gene expression profiles in mononuclear cells from bone marrow blood in relapsed or drug-resistant AML patients compared with AML remission and Healthy controls.

Of note, we found that the significantly overlapped up-regulated genes (i.e. EGFL7, CBX2, SOX4, and CDK6) in relapsed or drug-resistant AML patients are closely associated with biological processes related to AML progression and resistance, such as aberrant cell differentiation and transcription dysregulation. For example, early studies have demonstrated that the specific expression of SOX4 induces the initiation and development of leukaemia in zebrafish, mice, and humans [31, 32]. Recently, He et al. have reported that SOX4 regulates the expression of ARHGAP9, a drug-resistance-related gene, by directly binding to its promoter, thus interfering the proliferation, cycle, and apoptosis of AML cells and accelerating the disease progression and drug resistance of patients with AML [33]. Notably, the significantly overlapped down-regulated genes (i.e. LCN2, CYBB, RNAS, and CD48) are thought to dominate the regulation of the immune microenvironment and the response to inflammation during AML relapse or drug resistance. For instance, Zhang et al. demonstrated that CD48 overexpression can lead to the activation of NK cells and the enhancement of their killing activity against AML cells in vitro [34]. In contrast, the decreased expression of CD48 in AML patients helps AML cells avoid NK cells’ recognition [35]. Therefore, this study suggests that genes that are significantly differentially expressed in patients with relapsed or drug-resistant AML may serve as novel biomarkers for monitoring AML prognosis and targeted therapeutics.

RBPs are key controllers in mediating post-transcriptional gene regulation (PTGR), and they regulate the intracellular fate of individual transcripts via interactions with RNA-binding domains (RBDs) [36]. Herein, we report that numerous RBP genes are significantly differentially expressed in patients with AML relapse in comparison to AML remission and Healthy controls, strongly correlating with AML progression and drug resistance. Similarly, it has also been demonstrated that normal and leukaemic cells can be distinguished on the basis of differential RBP expression, indicating their ability to define cellular identity [37, 38]. Thus, by analysing AML progression- and drug resistance-related RBPs, we can evaluate the disease status of AML patients and infer survival probability. This, in turn, may lead to the identification of new therapeutic targets and personalised precision oncology in predicting AML prognosis.

RAS signalling is an important mechanism for regulating the diversities of gene expression and the proteome amongst eukaryotes [39]. However, abnormal expression of RAS in cells may lead to the development of various diseases, such as atherosclerosis as well as lung and pancreatic adenocarcinoma [40, 41]. Research has also shown that aberrant RAS is one of the leading factors involved in the regulation of AML drug resistance, and it is usually closely associated with poor prognosis and drug resistance in AML [42]. For instance, aminoacyl-tRNA synthetase-interacting multifunctional protein 2 (AIMP2) is a non-enzymatic component required for the multi-tRNA synthetase complex, while the exon 2 skipping alternatively spliced variant of AIMP2 (AIMP2-DX2) compromises AIMP2 activity and is strongly correlated with major cancer signalling pathways, poor prognosis, and drug resistance in AML. Indeed, further analysis of the clinical patient cohort reveals that AIMP2-DX2 positive AML patients show decreased sensitivities to anticancer drugs and overall survival [43]. Here, we unravel the significant difference of RASGs and RASEs in patients with AML relapse compared with AML remission and Healthy subjects, especially for both intronR and A5SS alternative splicing types. Further GO analysis proved that the differential expression of RASGs very likely participates in the regulation of key RASEs in AML by affecting large numbers of sophisticated biological processes, such as RNA splicing, transcriptional regulation, and protein stabilisation, thus increasing the drug resistance of AML cells. Our findings strongly suggest that differentially expressed RASGs and RASEs are closely related to the regulation of drug resistance in AML.

In conclusion, the aberrant function of RBPs and RAS in AML largely contributes to disease progression and drug resistance in AML patients. This indicates that the RBP-AS regulatory axis plays an important role in the formation of AML drug resistance. It is worth noting that abnormally expressed RBPs and RASEs may be used as potential biomarkers of AML prognosis or targets for therapeutics. Future elucidation of the specific mechanism of RBPs and RAS in the regulation of drug resistance is needed to shed light on the intricate molecular mechanisms of resistance regulation in AML. This will also provide a reliable research basis for the in-depth development of more efficacious therapeutics targeting AML drug resistance-related genes.

In summary, our studies have shown that the aberrance of RAS and RBPs are highly associated with the pathogenesis of AML. Notably, this study presents an overview of the aberrant RAS and differential expression of RBP genes in AML relapse and drug resistance and further highlights their close relation to disease progression and drug resistance in AML patients. An in-depth understanding of the regulatory mechanisms underlying AML relapse and drug resistance will largely contribute to the future development of strategies for AML prevention, theranostics, and prognostic monitoring, thereby increasing the overall survival of patients with AML.

AML acute myeloid leukaemia

HSCs haematopoietic stem cells

DEGs differentially expressed genes

RBPs RNA-binding proteins

mybl2 myb-related protein B gene

PTBP1 polypyrimidine tract-binding protein 1

FLT3-ITD internal tandem duplication mutations within FMS-like tyrosine kinase-3

AS alternative splicing

ATR anti-thrombin receptor

PCCs Pearson’s correlation coefficients

ASEs alternative splicing events

RASGs regulatory alternative splicing genes

RASEs regulatory alternative splicing events

RNA-seq RNA sequencing; reAML, AML relapse

GO gene ontology

KEGG kyoto encyclopedia of genes and genomes

PPI protein-protein interaction

WGCNA weighted gene co-expression network analysis

ES exon skipping; A5SS, alternative 5' splice site

A3SS alternative 3' splice site

MXE mutually exclusive exons

5pMXE mutually exclusive 5' UTRs

3pMXE mutually exclusive 3' UTRs

FPKM fragments per kilobase per million mapped reads

PTGR post-transcriptional gene regulation

Ara-C cytarabine

METTL3 methyltransferase 3

NK natural killer

RBDs RNA-binding domains

AIMP2 aminoacyl-tRNA synthetase-interacting multifunctional protein 2

AIMP2-DX2 exon 2 skipping alternatively spliced variant of AIMP2

Acknowledgements

The authors are grateful for the financial support from the National Nature Science Foundation of China, Shandong Science and Technology Agency, Health Commission of Shandong Province and Affiliated Hospital of Shandong University of Traditional Chinese Medicine.

Author contributions

YM Zhang and XY Dong contributed equally. JY Wang, YM Zhang and XY Dong conceived and designed the study. JY Wang, YM Zhang and XY Dong analysed the data and wrote the manuscript. JY Wang and YM Zhang supervised the study and revised the manuscript. W Zheng, J Xu and ZZ Wang analysed clinical samples and conducted the experiments. SM Ding and YY Wang collected clinical samples. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (No. 82104609), Natural Science Foundation of Shandong Province (No. ZR2023LZY002), Medical and Health Technology Development Plan of Shandong Province (No. 202003041150) and High-level Talents Project of Affiliated Hospital of Shandong University of Traditional Chinese Medicine (No. rc0000002-41).

Data Availability

All data are incorporated into the article and its online supplementary material.

Ethics approval and consent to participate

The studies involving human bone marrow blood samples were reviewed and approved by the Medical Institutional Ethics Committee of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine, China. Approval no., (2023) Review No.(143)-KY.

Consent for publication

All listed authors have actively participated in the study and have read and approved the submitted manuscript.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China.

²Institute of Hematology, Shandong University of Traditional Chinese Medicine, Jinan 250014, China.

³Key Laboratory of Integrated Traditional Chinese and Western Medicine for Hematology, Health Commission of Shandong Province, Jinan 250014, China.

Tahir SK, Calvo E. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 2023;141(17):2114–26.
Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med. 2022;28(6):1212–23.
Tettamanti S, Pievani A, Biondi A, Dotti G, Serafini M. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia. 2022;36(1):13–22.
Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14(1):49.
Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13(1):72.
Kantarjian H, Kadia T. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41.
Shimony S, Stahl M. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(3):502–26.
Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, et al. Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Front Oncol. 2021;11:656218.
Levin M, Stark M, Ofran Y, Assaraf YG. Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance. Cancer Cell Int. 2021;21(1):53.
Dam SH, Olsen LR, Vitting-Seerup K. Expression and splicing mediate distinct biological signals. BMC Biol. 2023;21(1):220.
Kolathur KK. Role of promoters in regulating alternative splicing. Gene. 2021;782:145523.
Jiang W, Chen L. Alternative splicing: Human disease and quantitative analysis from high-throughput sequencing. Comput Struct Biotechnol J. 2021;19:183–95.
Morales ML, García-Vicente R. Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia. Leukemia. 2023;37(8):1649–59.
Wang E, Aifantis I. RNA Splicing and Cancer. Trends Cancer. 2020;6(8):631–44.
Qin H, Ni H, Liu Y, Yuan Y, Xi T. RNA-binding proteins in tumor progression. J Hematol Oncol. 2020;13(1):90.
Sun YM, Wang WT, Zeng ZC, Chen TQ, Han C, Pan Q, et al. circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression. Blood. 2019;134(18):1533–46.
Hodson DJ. Breaking the loop in AML. Blood. 2023;142(1):6–7.
Bamezai S, Pulikkottil AJ. A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML. Blood. 2023;142(1):90–105.
Gill N, Dhillon B. RNA-seq Data Analysis for Differential Expression. Methods Mol Biol. 2022;2391:45–54.
Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511–5.
Liu S, Wang Z, Zhu R, Wang F, Cheng Y, Liu Y. Three Differential Expression Analysis Methods for RNA Sequencing: limma, EdgeR, DESeq2. J Vis Exp. 2021;(175).
Nomiri S, Karami H, Baradaran B, Javadrashid D, Derakhshani A, Nourbakhsh NS, et al. Exploiting systems biology to investigate the gene modules and drugs in ovarian cancer: A hypothesis based on the weighted gene co-expression network analysis. Biomed Pharmacother. 2022;146:112537.
Jin L, Li G, Yu D, Huang W, Cheng C, Liao S, et al. Transcriptome analysis reveals the complexity of alternative splicing regulation in the fungus Verticillium dahliae. BMC Genomics. 2017;18(1):130.
Wang K, Li L, Jin J, An Y, Wang Z, Zhou S, et al. Fatty acid synthase (Fasn) inhibits the expression levels of immune response genes via alteration of alternative splicing in islet cells. J Diabetes Complications. 2022;36(6):108159.
Bu D, Luo H, Huo P, Wang Z, Zhang S, He Z, et al. KOBAS-i: intelligent prioritization and exploratory visualization of biological functions for gene enrichment analysis. Nucleic Acids Res. 2021;49(W1):W317–25.
Hindley A, Catherwood MA, McMullin MF, Mills KI. Significance of NPM1 Gene Mutations in AML. Int J Mol Sci. 2021;22(18):10040.
Ketkar S, Verdoni AM, Smith AM, Bangert CV, Leight ER, Chen DY, et al. Remethylation of Dnmt3a(-/-) hematopoietic cells is associated with partial correction of gene dysregulation and reduced myeloid skewing. Proc Natl Acad Sci USA. 2020;117(6):3123–34.
Gurnari C, Pagliuca S, Visconte V. Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. Int J Mol Sci. 2020;21(22):8505.
Zhang B, Li D, Wang R. Transcriptome Profiling of N7-Methylguanosine Modification of Messenger RNA in Drug-Resistant Acute Myeloid Leukemia. Front Oncol. 2022;12:926296.
Fang S, Peng B, Wen Y, Yang J, Wang H, Wang Z, et al. Transcriptome-Wide Analysis of RNA N(6)-Methyladenosine Modification in Adriamycin-Resistant Acute Myeloid Leukemia Cells. Front Genet. 2022;13:833694.
Molina B, Chavez J. Zebrafish models of acute leukemias: Current models and future directions. Rev Dev Biol. 2021;10(6):e400.
Moreno CS. SOX4: The unappreciated oncogene. Semin Cancer Biol. 2020;67(Pt1):57–64.
He X, Zou H, Wang F. SOX4-induced upregulation of ARHGAP9 promotes the progression of acute myeloid leukemia. Drug Dev Res. 2021;82(8):1227–34.
Zhang T, Fang Q, Liu P, Wang P, Feng C, Wang J. Heme oxygenase 1 overexpression induces immune evasion of acute myeloid leukemia against natural killer cells by inhibiting CD48. J Transl Med. 2022;20(1):394.
Wang Z, Xiao Y, Guan W, Wang M, Chen J, Zhang L, et al. Acute myeloid leukemia immune escape by epigenetic CD48 silencing. Clin Sci. 2020;134(2):261–71.
Qin T, Cheng Y, Wang X. RNA-binding proteins as drivers of AML and novel therapeutic targets. Leuk Lymphoma. 2022;63(5):1045–57.
Liu Z, Spiegelman VS, Wang HG. Distinct noncoding RNAs and RNA binding proteins associated with high-risk pediatric and adult acute myeloid leukemias detected by regulatory network analysis. Cancer Rep. 2021;5(10):e1592.
Saha S, Murmu KC, Biswas M, Chakraborty S, Basu J, Madhulika S, et al. Transcriptomic Analysis Identifies RNA Binding Proteins as Putative Regulators of Myelopoiesis and Leukemia. Front Oncol. 2019;9:692.
Ule J, Blencowe BJ. Alternative Splicing Regulatory Networks: Functions, Mechanisms, and Evolution. Mol Cell. 2019;76(2):329–45.
Zhu L, Wang Z, Sun Y, Giamas G, Stebbing J, Yu Z, et al. A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma. Front Oncol. 2021;11:778637.
Chen B, Deng T, Deng L, Yu H, He B, Chen K, et al. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma. BMC Cancer. 2021;21(1):1211.
Mäkelä E, Pavic K, Varila T, Salmenniemi U, Löyttyniemi E, Nagelli SG. Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias. Clin Cancer Res. 2021;27(10):2848–60.
Ku J, Kim R, Kim D, Kim D, Song S, Lee K. Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer. Commun Biol. 2020;3(1):630.

No competing interests reported.

Additionalfile1SupplementaryFiguresandFigureLegend.docx
Additional file 1: Figure S1. Transcription profiles analysis of AML drug-resistant patients. A Bar plot exhibiting the most enriched KEGG results of the co-upregulated DEGs in two comparison groups (reAML vs Healthy & reAML vs AML). B Bar plot exhibiting the most enriched KEGG results of the co-downregulated DEGs in two comparison groups (reAML vsHealthy & reAML vs AML). C Box plot showing the expression level of EGFL7, CBX2, SOX4, CDK6, LCN2, CYBB, RNAS, and CD48 in the indicated groups. Error bars represent means ± SEM. ***p<0.001; **p<0.01; *p<0.05.Figure S2. The expression level of IGF2BP2, CDK6, and SOX4 of LAML in TCGA database. A Box plot showing the expression level of IGF2BP2 in LAML clinical data from TCGA. B Box plot showing the expression level of CDK6 in LAML clinical data from TCGA. C Box plot showing the expression level of SOX4 in LAML clinical data from TCGA.

Download PDF

Reviewers invited by journal
27 Aug, 2024
Editor assigned by journal
05 Jul, 2024
Submission checks completed at journal
05 Jul, 2024
First submitted to journal
05 Jul, 2024

You are reading this latest preprint version

Genome-wide investigation of differentially expressed alternative splicing and RNA-binding protein genes association with AML drug resistance

Status:

Version 1

Abstract

Figures

Introduction

Materials and methods

Patient samples

RNA extraction and sequencing

RNA-seq raw data cleaning and alignment

Differentially expressed genes (DEGs) analysis

Immune-related genes

WGCNA and co-expression analysis

Alternative splicing analysis

Functional enrichment analysis

Statistical analysis

Results

Discussion

Conclusions

Abbreviations

Declarations

References

Additional Declarations

Supplementary Files

Status:

Version 1